Clinical Trials Results - National Cancer Institute

Skip to content

NCI Home

Cancer Topics

Clinical Trials

Cancer Statistics

Research & Funding

News

About NCI


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 23 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 120				Pharmaceutical / Industry				CLBH589B2201 NCT00425555


2.		Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CLBH589B2212 NCT00490776


3.		A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer Whose Disease Has Progressed on or After Trastuzumab

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CLBH589C2204 NCT00567879


4.		A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				CLBH589B2102 NCT00621244


5.		LBH589 + Decitabine for Patients Age Greater That or Equal to 60 With High Risk Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia(AML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				60 and over				Other				08-0172 NCT00691938


6.		Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Approved-not yet active				18 and over				Other, Pharmaceutical / Industry				MCC-15461 IND 102483, LBH589, NCT00738751


7.		LBH589 Treatment for Refractory Clear Cell Renal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				SCRI GU 49 IND 79,340, NCT00550277


8.		LBH589 in Refractory Myelodysplastic Syndromes (MDS)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				SCRI MDS 07 79,698, NCT00594230


9.		Efficacy and Safety Study of Panobinostat in Patients With Metastatic Hormone Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				CLBH589C2208 NCT00667862


10.		Phase II Trial of LBH589 in Refractory Colorectal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				CLBH589BUS19T CRC GOLP CNOV 0823, NCT00690677

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute